Etanercept as a salvage treatment for refractory aplastic anemia
- 5 December 2008
- journal article
- case report
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 52 (4) , 522-525
Abstract
About 10–15% of patients with acquired aplastic anemia (AAA) have resistant/recurrent disease not eligible for standard treatment like hematopoietic stem cell transplantation and/or combined immunosuppression. We report a 17‐year‐old male with an 11 years history of AAA who, after two courses of immunosuppression, was red cell transfusion‐dependent, severely thrombocytopenic, refractory to platelet transfusion, had iron overload and post‐transfusion HCV infection. This patient achieved transfusion independence from platelets and normalized Hb after treatment with the anti‐TNF agent Etanercept. Over a 12 months follow‐up he experienced only transient increase of liver transaminases. Pediatr Blood Cancer 2009;52:522–525.Keywords
This publication has 16 references indexed in Scilit:
- Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemiaBlood, 2008
- Recent improvement in outcome of unrelated donor transplantation for aplastic anemiaBone Marrow Transplantation, 2007
- Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow TransplantationHaematologica, 2007
- Treatment of acquired aplastic anemiaHaematologica, 2007
- Current concepts in the pathophysiology and treatment of aplastic anemiaBlood, 2006
- Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemiaBone Marrow Transplantation, 2006
- Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survivalBlood, 2005
- Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled studyJournal of Hepatology, 2005
- TNF- and IFN- are overexpressed in the bone marrow of Fanconi anemia patients and TNF- suppresses erythropoiesis in vitroBlood, 2003
- Malignant Tumors Occurring after Treatment of Aplastic AnemiaNew England Journal of Medicine, 1993